Literature DB >> 21844323

Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents.

Norbert Schormann1, Charnell Inglis Sommers, Mark N Prichard, Kathy A Keith, James W Noah, Manunya Nuth, Robert P Ricciardi, Debasish Chattopadhyay.   

Abstract

Poxvirus uracil DNA glycosylase D4 in association with A20 and the catalytic subunit of DNA polymerase forms the processive polymerase complex. The binding of D4 and A20 is essential for processive polymerase activity. Using an AlphaScreen assay, we identified compounds that inhibit protein-protein interactions between D4 and A20. Effective interaction inhibitors exhibited both antiviral activity and binding to D4. These results suggest that novel antiviral agents that target the protein-protein interactions between D4 and A20 can be developed for the treatment of infections with poxviruses, including smallpox.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844323      PMCID: PMC3195037          DOI: 10.1128/AAC.00278-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

3.  A yellow fluorescent protein-based assay for high-throughput screening of glycine and GABAA receptor chloride channels.

Authors:  Wade Kruger; Daniel Gilbert; Rebecca Hawthorne; Deanne H Hryciw; Stephan Frings; Philip Poronnik; Joseph W Lynch
Journal:  Neurosci Lett       Date:  2005-02-23       Impact factor: 3.046

4.  A comparison of assay performance measures in screening assays: signal window, Z' factor, and assay variability ratio.

Authors:  Philip W Iversen; Brian J Eastwood; G Sitta Sittampalam; Karen L Cox
Journal:  J Biomol Screen       Date:  2006-02-20

Review 5.  Update on new antivirals under development for the treatment of double-stranded DNA virus infections.

Authors:  L K Dropulic; J I Cohen
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

6.  Identification of inhibitors that block vaccinia virus infection by targeting the DNA synthesis processivity factor D4.

Authors:  Manunya Nuth; Lijuan Huang; Yih Ling Saw; Norbert Schormann; Debasish Chattopadhyay; Robert P Ricciardi
Journal:  J Med Chem       Date:  2011-04-19       Impact factor: 7.446

7.  Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus.

Authors:  Emma A Harden; Ruth Falshaw; Susan M Carnachan; Earl R Kern; Mark N Prichard
Journal:  Antiviral Res       Date:  2009-07-01       Impact factor: 5.970

8.  A novel vascular relaxing agent, N-(6--aminohexyl)-5-chloro-1-naphthalensulfonamide which affects vascular smooth muscle actomyosin.

Authors:  H Hidaka; M Asano; S Iwadare; I Matsumoto; T Totsuka; N Aoki
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

9.  Origin-independent plasmid replication occurs in vaccinia virus cytoplasmic factories and requires all five known poxvirus replication factors.

Authors:  Frank S De Silva; Bernard Moss
Journal:  Virol J       Date:  2005-03-22       Impact factor: 4.099

10.  ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.

Authors:  Robert Jordan; Arthur Goff; Annie Frimm; Michael L Corrado; Lisa E Hensley; Chelsea M Byrd; Eric Mucker; Josh Shamblin; Tove' C Bolken; Carly Wlazlowski; Wendy Johnson; Jennifer Chapman; Nancy Twenhafel; Shanthakumar Tyavanagimatt; Adams Amantana; Jarasvech Chinsangaram; Dennis E Hruby; John Huggins
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.938

View more
  10 in total

Review 1.  The vaccinia virus DNA polymerase and its processivity factor.

Authors:  Maciej W Czarnecki; Paula Traktman
Journal:  Virus Res       Date:  2017-02-01       Impact factor: 3.303

Review 2.  Poxvirus uracil-DNA glycosylase-An unusual member of the family I uracil-DNA glycosylases.

Authors:  Norbert Schormann; Natalia Zhukovskaya; Gregory Bedwell; Manunya Nuth; Richard Gillilan; Peter E Prevelige; Robert P Ricciardi; Surajit Banerjee; Debasish Chattopadhyay
Journal:  Protein Sci       Date:  2016-11-02       Impact factor: 6.725

3.  Structural analysis of point mutations at the Vaccinia virus A20/D4 interface.

Authors:  Céline Contesto-Richefeu; Nicolas Tarbouriech; Xavier Brazzolotto; Wim P Burmeister; Christophe N Peyrefitte; Frédéric Iseni
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2016-08-09       Impact factor: 1.056

Review 4.  Orthopoxvirus targets for the development of new antiviral agents.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Antiviral Res       Date:  2012-03-08       Impact factor: 10.103

5.  Crystal structure of the vaccinia virus DNA polymerase holoenzyme subunit D4 in complex with the A20 N-terminal domain.

Authors:  Céline Contesto-Richefeu; Nicolas Tarbouriech; Xavier Brazzolotto; Stéphane Betzi; Xavier Morelli; Wim P Burmeister; Frédéric Iseni
Journal:  PLoS Pathog       Date:  2014-03-06       Impact factor: 6.823

Review 6.  The French Armed Forces Virology Unit: A Chronological Record of Ongoing Research on Orthopoxvirus.

Authors:  Déborah Delaune; Frédéric Iseni; Audrey Ferrier-Rembert; Christophe N Peyrefitte; Olivier Ferraris
Journal:  Viruses       Date:  2017-12-23       Impact factor: 5.048

Review 7.  Inhibitors of DNA Glycosylases as Prospective Drugs.

Authors:  Grigory V Mechetin; Anton V Endutkin; Evgeniia A Diatlova; Dmitry O Zharkov
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

8.  A 3D structural SARS-CoV-2-human interactome to explore genetic and drug perturbations.

Authors:  Shayne D Wierbowski; Siqi Liang; Yuan Liu; You Chen; Shagun Gupta; Nicole M Andre; Steven M Lipkin; Gary R Whittaker; Haiyuan Yu
Journal:  Nat Methods       Date:  2021-11-29       Impact factor: 47.990

Review 9.  Mono- and combinational drug therapies for global viral pandemic preparedness.

Authors:  Aleksandr Ianevski; Rouan Yao; Ronja M Simonsen; Vegard Myhre; Erlend Ravlo; Gerda D Kaynova; Eva Zusinaite; Judith M White; Stephen J Polyak; Valentyn Oksenych; Marc P Windisch; Qiuwei Pan; Eglė Lastauskienė; Astra Vitkauskienė; Algimantas Matukevičius; Tanel Tenson; Magnar Bjørås; Denis E Kainov
Journal:  iScience       Date:  2022-03-17

Review 10.  Defining Pharmacological Targets by Analysis of Virus-Host Protein Interactions.

Authors:  Manuel Llano; Mario A Peña-Hernandez
Journal:  Adv Protein Chem Struct Biol       Date:  2017-12-18       Impact factor: 3.507

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.